Genetic and antibody-mediated inhibition of CD40 or CD40L successfully reduced disease burden in experimental models of atherosclerosis, Crohn’s disease, psoriasis, rheumatoid arthritis (RA), and experimental autoimmune encephalomyelitis (EAE) (14). This evidence concerns the gene CD40 and experimental autoimmune encephalomyelitis.